Study guide

1.18 Neuromuscular Disease & Fragile X Spectrum

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

1.18 Neuromuscular Disease & Fragile X Spectrum

Key Takeaways Explain This Topic AI

DMD is typically out-of-frame DMD variants with absent dystrophin; BMD is often in-frame with residual dystrophin—both are X-linked and require carrier cardiomyopathy surveillance counseling

Myotonic dystrophy type 1 shows CTG anticipation in DMPK; congenital DM1 is almost always maternally transmitted

SMA is AR SMN1-related; SMN2 copy number modifies severity and informs prognosis counseling alongside modern disease-modifying therapies

FMR1 CGG categories (normal, intermediate, premutation, full mutation) map to FXS, FXTAS, and FXPOI with distinct counseling agendas

Neuromuscular and Fragile X stems reward precise inheritance language: X-linked dystrophinopathy carriers, AD CTG expansion risk, AR SMA residual risk, and X-linked Fragile X transmission rules

Last updated: August 2026

1.18 Neuromuscular Disease & Fragile X Spectrum

Quick Answer: DMD/BMD = X-linked DMD (frame shift → DMD; in-frame → BMD) + carrier heart surveillance; DM1 = DMPK CTG anticipation (congenital = maternal); SMA = biallelic SMN1 loss, SMN2 copies modify severity; Fragile X = FMR1 CGG tiers → FXS / FXTAS / FXPOI.

These conditions are Domain 1C staples because they combine classic phenotypes with inheritance traps genetic counselors must explain without oversimplification.

Duchenne & Becker Muscular Dystrophy

Pathogenic variants in DMD (Xp21) disrupt dystrophin. Inheritance is X-linked . The reading-frame rule is the highest-yield molecular teaching point:

Condition Typical molecular theme Clinical tempo

Duchenne (DMD) Out-of-frame deletions/duplications or nonsense → little/no dystrophin Early childhood proximal weakness, calf pseudohypertrophy, Gowers sign, loss of ambulation in childhood (historic natural history), cardiomyopathy, respiratory decline

Becker (BMD) Often in-frame deletions → truncated but partially functional dystrophin Later onset, milder skeletal course, still significant cardiomyopathy risk

Carrier Counseling (Do Not Skip)

Manifesting or non-manifesting female carriers can have elevated CK , mild weakness, and—critically— dilated cardiomyopathy . Exam stems that stop at “carriers are asymptomatic” are wrong. Cascade testing of maternal relatives, CK/cardiac surveillance referrals for carriers, and reproductive options (including prenatal/PGT discussions) are core GC tasks.

Germline mosaicism: A mother of an isolated affected son with negative leukocyte testing for the familial variant may still have recurrence risk due to germline mosaicism—quote empiric residual risk rather than absolute zero.

CK tip: Markedly elevated CK in a boy with proximal weakness supports dystrophinopathy workup (genetic testing ± muscle biopsy historically). Female relatives with high CK need carrier evaluation.

Myotonic Dystrophy Type 1 (DM1)

DM1 is caused by a CTG trinucleotide repeat expansion in the DMPK 3′ UTR. Inheritance is autosomal dominant with anticipation (increasing expansion and earlier/more severe disease in successive generations).

Feature Counseling anchor

Multisystem phenotype Myotonia, distal weakness, cataracts, arrhythmias/conduction block, endocrine issues, cognitive/behavioral features variable

Anticipation Expansions can enlarge intergenerationally—especially through maternal transmission for very large alleles

Congenital DM1 Severe neonatal hypotonia, respiratory insufficiency, talipes; almost always maternally transmitted large expansions

Testing PCR may miss huge expansions—Southern blot / specialized methods needed for full characterization

Exam trap: Do not confuse DM1 (CTG DMPK ) with DM2 (CCTG CNBP ), which has less congenital anticipation narrative. For CGC Domain 1C, DM1 anticipation + congenital maternal transmission is the tested pearl.

Cardiac conduction disease makes preoperative counseling and cascade family cardiac screening part of the GC conversation even when the consult started as “muscle stiffness.”

Spinal Muscular Atrophy (SMA)

5q SMA is typically biallelic pathogenic variants in SMN1 (most commonly homozygous exon 7 deletion). Inheritance is autosomal recessive . A nearly identical paralog, SMN2 , produces limited full-length SMN protein; SMN2 copy number inversely correlates with severity on average (more copies → milder phenotypes), though modifiers exist.

  • SMA type (classic) Onset theme SMN2 tendency
  • Type 1 (Werdnig-Hoffmann) Infantile, never sits, historically high early mortality Often 2 copies
  • Type 2 Sits, does not walk independently Intermediate
  • Type 3 (Kugelberg-Welander) Walks, later progressive weakness Higher copy numbers more often
  • Type 4 Adult onset Highest copy numbers

Counseling points for the exam:

Carrier testing must account for [2+0] silent carriers (two SMN1 copies on one allele, none on the other)—standard dosage carrier screens can be falsely reassuring; residual risk counseling matters.

Newborn screening and early therapy (e.g., nusinersen, onasemnogene abeparvovec, risdiplam—know that disease-modifying options exist and timing matters) change the prognostic script families heard historically.

Partners of known carriers need carrier screening with residual-risk explanation.

Fragile X Spectrum ( FMR1 CGG Repeats)

Fragile X–associated disorders arise from CGG repeat expansion in the FMR1 5′ UTR, with methylation silencing at full mutation sizes. Categories (approximate clinical teaching ranges used on exams):

  • Category Approx. CGG repeats Primary counseling phenotype
  • Normal ~5–44 Not associated with FXS/FXTAS/FXPOI
  • Intermediate (gray zone) ~45–54 Generally stable-ish; small expansion risk—context-specific counseling

Premutation ~55–200 FXTAS (late-onset tremor/ataxia, more in males), FXPOI (female ovarian insufficiency), anxiety/other neuropsychiatric risks; can expand to full mutation in offspring (especially maternal transmission)

Full mutation >200 (with methylation) Fragile X syndrome (FXS) : ID, autism features, long face/large ears/macroorchidism post-puberty in males; females variable due to X-inactivation

Transmission Rules Genetic Counselors Must State Clearly

Full-mutation FXS is X-linked: males with full mutation are typically more severely affected; females vary.

Premutation mothers can transmit expanded alleles that become full mutations—size and sex-of-parent effects matter; maternal premutations are the classic route to FXS children.

Premutation fathers transmit the premutation to all daughters (who then may expand in the next generation) but typically do not transmit to sons (X-linked).

Do not tell a premutation carrier she “has Fragile X syndrome.” She needs FXPOI/FXTAS risk counseling and reproductive expansion risk—not an FXS diagnosis.

  • Spectrum condition Who Counseling focus
  • FXS Full mutation Developmental supports, cascade testing, reproductive options
  • FXTAS Premutation (esp. older males) Neurology referral, family cascade for reproductive-age relatives

FXPOI Premutation females Fertility timeline, reproductive endocrinology, reproductive options, expansion risk to offspring

Integrating Neuromuscular + Fragile X Stems

When a vignette mixes hypotonia and developmental delay, sort by tempo and extras :

  • Clue Lean toward
  • Calf hypertrophy, huge CK, X-linked pedigree Dystrophinopathy
  • Grip myotonia, cataracts, AD anticipation, congenital hypotonia with maternal DM1 DM1
  • Symmetric proximal weakness, tongue fasciculations, AR, SMN1 del SMA
  • Large ears, ID/autism, maternal ID or FXPOI, CGG testing Fragile X

Always end with cascade testing strategy and—when relevant—cardiac (DMD carriers, DM1) or reproductive endocrine (FXPOI) referrals. These conditions illustrate Domain 2 anticipation/penetrance concepts with Domain 1 phenotypes.